PillRx only · Injection · Intravenous
Meropenem
Meropenem
9 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US20 NDCs
9 active makers
9 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$4.838
Latest avg · Jul 22, 2026
-14%
Since Dec 17, 2025
9
Active US suppliers
43%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
4.4K
Rx · 2026 Q1
53K
Units dispensed
+50%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it9 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| BROOKS STERISCIENCE LIMITED | unknown | 7 | SUPPLYING |
| Armas Pharmaceuticals Inc. | unknown | 6 | SUPPLYING |
| Sandoz Inc | unknown | 4 | SUPPLYING |
| Civica, Inc. | unknown | 4 | SUPPLYING |
| Qilu Antibiotics Pharmaceutical Co., Ltd. | unknown | 2 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
| Savior Lifetec Corporation | unknown | 2 | SUPPLYING |
| Gland Pharma Limited | unknown | 2 | SUPPLYING |
| Mylan Institutional LLC | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.